• Barclays Bank, 2008

    In the midst of the financial crisis, Barclays (the world's 4th largest bank by assets) is forced by UK regulators to raise more capital. Should it take up the UK government's offer to invest, or take funding from investors from the Middle East? Students may price the two deals to determine which is more expensive, and must decide whether avoiding the constraints of government ownership is worth the extra cost.
    詳細資料
  • Barclays Bank and Contingent Capital Notes, 2012, Spreadsheet Supplement

    Spreadsheet supplement for case 214063.
    詳細資料
  • ISS A/S: The Buyout, Spreadsheet Supplement

    Spreadsheet supplement to case 214027.
    詳細資料
  • Mylan Lab's Proposed Merger with King Pharmaceutical (Abridged), Spreadsheet Supplement

    Spreadsheet supplement for case 209097. Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders, but the merger does not look likely to be approved by Mylan shareholders, who must vote upon it. If Perry can swing the voting in favor of the deal, it will gain handsomely on its King shares without facing any corresponding losses on its Mylan holdings since those are hedged. Carl Icahn, another shareholder in Mylan, opposed the deal and sued Perry for alleged vote buying.
    詳細資料
  • Barclays Bank, 2008, Spreadsheet Supplement

    Spreadsheet supplement for case 213073.
    詳細資料
  • ISS A/S: The Buyout

    Provides the opportunity to value a leveraged buy-out; and to examine the nature and extent of a company's responsibilities to its bondholders. Here, the context is a "going private" transaction in Europe, where the financing plan called for the addition to the company's balance sheet of a significant amount of new debt and a reshaping of the capital structure. While leveraged buyouts had been used in Europe for several years, this was likely the first LBO done with a company that had publicly traded investment grade debt outstanding. The increased debt from the deal would increase the risk to the company and to the existing bonds, and the bonds' prices would fall significantly as a result. Students can use discounted cash flow techniques to value the LBO. They can then consider the wisdom of undertaking the LBO at the offered price, and work out a sensible debt schedule for the company. Students must also evaluate the effect of the transaction on the existing bonds, and understand the principles governing contractual duties (and how they differ from fiduciary obligations) towards bondholders (accounting for a business and social culture outside the United States) in order to determine the best course of action for the private equity buyers.
    詳細資料
  • Mylan Laboratories' Proposed Merger with King Pharmaceutical

    Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders, but the merger does not look likely to be approved by Mylan shareholders, who must vote upon it. If Perry can swing the voting in favor of the deal, it will gain handsomely on its King shares without facing any corresponding losses on its Mylan holdings since those are hedged. Carl Icahn, another shareholder in Mylan, opposed the deal and sued Perry for alleged vote buying.
    詳細資料
  • Barclays Bank and Contingent Capital Notes, 2012

    In 2012, regulatory changes following the financial crisis mean that Barclays Bank is faced with the need to raise large amounts of capital in order to comply with increased capital requirements, tightening rules as to the "quality of capital," and increased risk weights for its capital markets assets. The bank is contemplating offering contingent capital bonds, which would act like debt during "normal times" but would convert to create capital should the bank hit a "triggering event." How should these instruments be designed? Can they be attractive for the bank and for investors?
    詳細資料
  • The TELUS Share Conversion Proposal

    On February 21, 2013, TELUS announced a proposal to convert the firm's non-voting shares into voting shares on a one-to-one basis, thereby eliminating the firm's dual class structure. Shareholders were scheduled to vote on the proposal at the firm's annual general meeting (AGM) on May 9, 2013. Despite strong support from management, the board, two proxy advisory firms, and several large shareholders, the proposal was opposed by Mason Capital Management, a New York-based hedge fund. Mason, which controlled almost 20% of the voting shares and a large short position in the non-voting shares, had filed a dissident proxy circular recommending that shareholders vote against the proposal based on both procedural and substantive grounds. With the success of the vote in doubt, the board had to decide what to do. Should they proceed with the vote as planned, postpone the vote with the intention of re-introducing the proposal at some point in the future, or cancel the proposal for good? And what should they do with Mason, which management viewed as an "empty voter" in this matter?
    詳細資料
  • The TELUS Share Conversion Proposal, Spreadsheet Supplement

    A proxy battle between a Canadian firm and a US hedge fund over a proposal to unify the firm's dual class share structure.
    詳細資料
  • Aqua Bounty Courseware

    Spreadsheet supplement for case 213047.
    詳細資料
  • Aqua Bounty

    Valuation of a pre-revenue biotech company at IPO using probability trees and real option techniques. Company is based in Massachusetts and lists in London on AIM. Products are genetically-modified fast-growing salmon for fish farmers and disease-prevention drugs and diagnostic kits for farmed shrimp.
    詳細資料
  • British Land Spreadsheet Supplement

    Spreadsheet supplement to case 208-064.
    詳細資料
  • AXA MONY, Spreadsheet Supplement

    Spreadsheet Supplement for 208062.
    詳細資料
  • Mylan Lab's Proposed Merger with King Pharmaceutical (Abridged)

    Perry Capital owns shares in King and, to facilitate approval of the merger, buys shares in Mylan, whilst hedging out its economic exposure to Mylan's share price using derivatives. The price at which Mylan proposes to merge with King is generous to King shareholders, but the merger does not look likely to be approved by Mylan shareholders, who must vote upon it. If Perry can swing the voting in favor of the deal, it will gain handsomely on its King shares without facing any corresponding losses on its Mylan holdings since those are hedged. Carl Icahn, another shareholder in Mylan, opposed the deal and sued Perry for alleged vote buying.
    詳細資料
  • AXA MONY

    AXA's friendly bid for MONY is contested by activist hedge funds suspicious of management's generous change in control contracts. Votes trade after the record date. AXA financed the bid using an unusual conditionally convertible bond which may have affected incentives to trade and vote MONY shares.
    詳細資料
  • British Land

    British Land's shares traded below NAV. Laxey investments tried to force British Land into share buybacks and criticized its corporate governance. Laxey voted borrowed shares at the AGM.
    詳細資料
  • Introduction to Valuation Multiples

    Outlines the definition and applicability of financial multiples and their relationship to discounted cash flow analysis.
    詳細資料
  • Subscriber Models, Spreadsheet Supplement

    Spreadsheet Supplement for case 205061.
    詳細資料
  • Subscriber Models

    Introduces the subscriber model as an alternative valuation framework for firms whose revenues can be traced to repeated transactions with customers.
    詳細資料